GOLDMAN SACHS GROUP INC - BIOXCEL THERAPEUTICS INC ownership

BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 95 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.0%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of BIOXCEL THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$126,677
+97.3%
98,967
+334.6%
0.00%
Q1 2024$64,211
+13.4%
22,770
+18.6%
0.00%
Q4 2023$56,640
-83.2%
19,200
-85.6%
0.00%
Q3 2023$336,171
-65.0%
132,874
-7.8%
0.00%
Q2 2023$959,346
-68.6%
144,046
-12.0%
0.00%
-100.0%
Q1 2023$3,053,710
+166.1%
163,650
+206.3%
0.00%
Q4 2022$1,147,547
+103656.5%
53,424
-42.9%
0.00%
Q3 2022$1,106
+15.3%
93,509
+28.7%
0.00%
Q2 2022$959
-99.9%
72,674
+5.7%
0.00%
Q1 2022$1,437,000
+42.1%
68,748
+38.2%
0.00%
Q4 2021$1,011,000
-7.3%
49,734
+38.3%
0.00%
Q3 2021$1,091,000
-78.9%
35,969
-79.7%
0.00%
-100.0%
Q2 2021$5,160,000
-5.5%
177,590
+40.4%
0.00%0.0%
Q1 2021$5,458,000
-53.0%
126,465
-49.7%
0.00%
-66.7%
Q4 2020$11,617,000
+77.9%
251,443
+66.9%
0.00%
+50.0%
Q3 2020$6,530,000
+23.2%
150,611
+50.6%
0.00%0.0%
Q2 2020$5,300,000
+374.9%
99,979
+100.3%
0.00%
Q1 2020$1,116,000
+1038.8%
49,911
+370.0%
0.00%
Q2 2018$98,000
-65.6%
10,620
-61.9%
0.00%
Q1 2018$285,00027,8800.00%
Other shareholders
BIOXCEL THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
Logos Global Management LP 430,000$19,866,0001.70%
APIS CAPITAL ADVISORS, LLC 20,000$924,0000.89%
Avidity Partners Management LP 547,000$25,271,0000.82%
Knoll Capital Management, LLC 20,000$924,0000.63%
Artemis Investment Management LLP 1,013,448$46,839,0000.49%
AlphaCentric Advisors LLC 25,000$1,155,0000.48%
First Light Asset Management, LLC 94,202$4,352,0000.32%
Ikarian Capital, LLC 150,000$6,930,0000.31%
Longitude (Cayman) Ltd. 8,000$370,0000.18%
AllSquare Wealth Management LLC 5,490$254,0000.17%
View complete list of BIOXCEL THERAPEUTICS INC shareholders